Dexlansoprazole

Identification

Summary

Dexlansoprazole is a proton pump inhibitor used to treat erosive esophagitis, heartburn, and gastroesophageal reflux disease (GERD).

Brand Names
Dexilant
Generic Name
Dexlansoprazole
DrugBank Accession Number
DB05351
Background

Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of Lansoprazole, which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes Pantoprazole, Omeprazole, and Lansoprazole),6 dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.1,3,6,9 Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.10

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 369.36
Monoisotopic: 369.075882366
Chemical Formula
C16H14F3N3O2S
Synonyms
  • (+)-2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
  • (R)-LANSOPRAZOLE
  • 1H-BENZIMIDAZOLE, 2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-
  • 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
  • Dexlansoprazole
  • LANSOPRAZOLE R-FORM
  • LANSOPRAZOLE, (R)-
External IDs
  • NSC-758710
  • T-168390
  • TAK 390
  • TAK-390
  • TAK-390MR
  • TAK390

Pharmacology

Indication

Dexlansoprazole is a proton pump inhibitor (PPI) indicated for the:

  • Healing of all grades of erosive esophagitis (EE) for up to eight weeks in patients 12 years of age and older.10
  • Maintenance of healed EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age.10,11
  • Treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks in patients 12 years of age and older.10,11
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofErosive esophagitis•••••••••••••••••••• ••••••• •••••••
Management ofHeartburn••••••••••••••••••••••••• ••••••• •••••••• ••••••• •••••• ••••••••••••••• ••••••• •••••••
Management ofHeartburn•••••••••••••••••••••••••••••• ••••••• •••••••• ••••••• •••••• ••••••••••••••• ••••••• •••••••
Management ofHealed erosive esophagitis••••••••••••••••••••••••• ••••••• •••••••• ••••••• •••••• ••••••••••••••• ••••••• •••••••
Management ofHealed erosive esophagitis•••••••••••••••••••••••••••••• ••••••• •••••••• ••••••• •••••• ••••••••••••••• ••••••• •••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses both basal and stimulated gastric acid secretion.10 PPIs are associated with a risk for a rebound effect and a short-term increase in hypersecretion; thus, such risk cannot be excluded with dexlansoprazole.8 With long-term use, PPIs are also associated with a risk of increased susceptibility to bacterial infections, vitamin B12 and iron deficiency, and hypomagnesemia and hypocalcemia, possibly leading to osteoporosis and bone fractures.7

Dexlansoprazole is reported to interfere with the secretin stimulation test and create false positive urine screening tests for tetrahydrocannabinol. Dexlansoprazole can increase gastrin levels, which can cause enterochromaffin-like cell hyperplasia and increase serum CgA levels. Increased CgA levels may cause false positive results in diagnostic investigations for neuroendocrine tumours.10

Mechanism of action

Dexlansoprazole suppresses gastric acid secretion by blocking the final step of acid production. It inhibits the H/K ATPase at the secretory surface of the gastric parietal cell, which is involved in the secretion of hydrochloric acid.10 H/K ATPase is a proton pump responsible for hydrolyzing ATP and exchanging H+ ions from the cytoplasm for K+ ions in the secretory canaliculus: this action results in hydrochloric acid secretion into the gastric lumen.2

TargetActionsOrganism
APotassium-transporting ATPase alpha chain 1
inhibitor
Humans
APotassium-transporting ATPase subunit beta
inhibitor
Humans
UN(G),N(G)-dimethylarginine dimethylaminohydrolase 1Not AvailableHumans
Absorption

The dual delayed-release formulation of dexlansoprazole results in a plasma concentration-time profile with two distinct peaks; the first peak occurs one to two hours after administration, followed by a second peak within four to five hours. About 25% of the dose is released at the pH level of 5.5 in the proximal duodenum, while the other 75% is released in the distal small intestine at the pH level of 6.75.2,10

After oral administration of dexlansoprazole 30 or 60 mg to healthy subjects and symptomatic GERD patients, mean Cmax and AUC values of dexlansoprazole increased approximately dose-proportionally. Following administration of 30 mg in healthy adults, the mean (%CV) Cmax and AUC were 658 (40%) ng/mL and 3275 (47%) ng x h/mL, respectively. At a dose of 60 mg, the mean (%CV) Cmax and AUC were 1397 (51%) ng/mL and 6529 (60%) ng x h/mL, respectively. In healthy subjects, food increased Cmax by 12 to 55% and AUC by 9 to 37%. The effect of food on Tmax varied, as both an increase and a decrease was observed.10

Volume of distribution

The apparent volume of distribution (Vz/F) after multiple doses in symptomatic GERD patients was 40 L.10

Protein binding

Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.10

Metabolism

Dexlansoprazole is extensively metabolized in the liver. It undergoes oxidation and reduction, followed by subsequent sulfation, glucuronidation, and glutathione conjugation to form inactive metabolites. Oxidative metabolites are formed from CYP2C19-mediated hydroxylation and CYP3A4-mediated oxidation to the sulfone.5,10

CYP2C19 is a polymorphic liver enzyme which exhibits three phenotypes in the metabolism of CYP2C19 substrates: extensive metabolizers (1/1), intermediate metabolizers (*1/mutant) and poor metabolizers (mutant/mutant). Dexlansoprazole is the major circulating component in plasma regardless of CYP2C19 metabolizer status. In CYP2C19 intermediate and extensive metabolizers, the major plasma metabolites are 5-hydroxy dexlansoprazole and its glucuronide conjugate, while in CYP2C19 poor metabolizers dexlansoprazole sulfone is the major plasma metabolite.10

Hover over products below to view reaction partners

Route of elimination

Dexlansoprazole does not appear to be eliminated unchanged in the urine.4,10 Following the administration of [14C] dexlansoprazole to six healthy male subjects, approximately 50.7% (standard deviation (SD): 9.0%) of the administered radioactivity was excreted in urine and 47.6% (SD: 7.3%) in the feces.10

Half-life

Dexlansoprazole is eliminated with a half-life of approximately one to two hours.4,10

Clearance

Apparent clearance (CL/F) in healthy subjects was 11.4 to 11.6 L/hour, respectively, after five days of 30 or 60 mg once daily administration.10

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Oral LD50 value in mice, rats and dogs is reported to be > 5000 mg/kg.12

There have been no reports of significant overdose with dexlansoprazole. Multiple doses of 120 mg and a single dose of 300 mg did not result in death or other severe adverse events; however, serious adverse events of hypertension have been reported in association with twice daily doses of 60 mg. Nonserious adverse reactions observed with twice daily doses of 60 mg include hot flashes, contusion, oropharyngeal pain, and weight loss. Dexlansoprazole is not expected to be removed from the circulation by hemodialysis. In the event of over-exposure, treatment should be symptomatic and supportive.10

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbametapirThe serum concentration of Dexlansoprazole can be increased when it is combined with Abametapir.
AbataceptThe metabolism of Dexlansoprazole can be increased when combined with Abatacept.
AbrocitinibThe metabolism of Abrocitinib can be decreased when combined with Dexlansoprazole.
AcenocoumarolThe risk or severity of bleeding can be increased when Dexlansoprazole is combined with Acenocoumarol.
AdalimumabThe metabolism of Dexlansoprazole can be increased when combined with Adalimumab.
Food Interactions
  • Avoid St. John's Wort. It may induce the CYP3A4 metabolism of dexlansoprazole, possibly leading to reduced efficacy.
  • Take with or without food. Dexlansoprazole's dual delayed release formulation allows it to be taken without regard to food in contrast to other PPIs.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Dexlansoprazole sesquihydrateHS2S9VK3NH313640-86-7XTQWZVSRVXCIGB-BBBDYAHLSA-N
Product Images
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DexilantCapsule, delayed release60 mgNasogastric; OralTakeda2010-08-05Not applicableCanada flag
DexilantCapsule, delayed release60 mg/1OralA-S Medication Solutions2010-04-12Not applicableUS flag
DexilantCapsule, delayed release30 mgNasogastric; OralTakeda2010-08-05Not applicableCanada flag
DexilantCapsule, delayed release60 mg/1OralTakeda Pharmaceuticals America, Inc.2010-04-12Not applicableUS flag
DexilantCapsule, delayed release60 mg/1OralCardinal Health 107, LLC2010-04-122025-04-30US flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DexlansoprazoleCapsule, delayed release60 mg/1Oralbryant ranch prepack2022-11-22Not applicableUS flag
DexlansoprazoleCapsule, delayed release60 mg/1OralREMEDYREPACK INC.2023-03-28Not applicableUS flag
DexlansoprazoleCapsule, delayed release30 mg/1Oralbryant ranch prepack2023-06-10Not applicableUS flag
DexlansoprazoleCapsule, delayed release pellets60 mg/1OralMylan Pharmaceuticals Inc.2024-01-22Not applicableUS flag
DexlansoprazoleCapsule, delayed release30 mg/1OralPar Pharmaceutical, Inc.2023-06-10Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DEXGARD 30/30 MG MR KAPSUL, 30 ADETDexlansoprazole (30 mg) + Domperidone (30 mg)CapsuleOralNUVOMED İLAÇ SAN.TİC. A.Ş.2012-07-31Not applicableTurkey flag
DEXGARD 30/30 MG MR KAPSUL, 60 ADETDexlansoprazole (30 mg) + Domperidone (30 mg)CapsuleOralNUVOMED İLAÇ SAN.TİC. A.Ş.2012-07-31Not applicableTurkey flag
DUEDOM 30/10 MG KAPSÜL, 30 ADETDexlansoprazole (30 mg) + Domperidone (10 mg)CapsuleOralCELTİS İLAÇ SAN. VE TİC. A.Ş.2011-12-22Not applicableTurkey flag
DUEDOM 60/10 MG KAPSÜL, 30 ADETDexlansoprazole (60 mg) + Domperidone (10 mg)CapsuleOralCELTİS İLAÇ SAN. VE TİC. A.Ş.2011-12-22Not applicableTurkey flag

Categories

ATC Codes
A02BC06 — Dexlansoprazole
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Sulfinylbenzimidazoles
Direct Parent
Sulfinylbenzimidazoles
Alternative Parents
Methylpyridines / Alkyl aryl ethers / Benzenoids / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 4 more
Substituents
Alkyl aryl ether / Alkyl fluoride / Alkyl halide / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Ether / Heteroaromatic compound / Hydrocarbon derivative
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
UYE4T5I70X
CAS number
138530-94-6
InChI Key
MJIHNNLFOKEZEW-RUZDIDTESA-N
InChI
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
IUPAC Name
2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl]-1H-1,3-benzodiazole
SMILES
CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1

References

General References
  1. Behm BW, Peura DA: Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):439-45. doi: 10.1586/egh.11.37. [Article]
  2. Skrzydlo-Radomanska B, Radwan P: Dexlansoprazole - a new-generation proton pump inhibitor. Prz Gastroenterol. 2015;10(4):191-6. doi: 10.5114/pg.2015.56109. Epub 2015 Dec 16. [Article]
  3. Frye JW, Peura DA: Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR. Ther Clin Risk Manag. 2015 Oct 30;11:1649-56. doi: 10.2147/TCRM.S66680. eCollection 2015. [Article]
  4. Wittbrodt ET, Baum C, Peura DA: Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis. Clin Exp Gastroenterol. 2009;2:117-28. Epub 2009 Nov 17. [Article]
  5. Grabowski B, Lee RD: Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects. Clin Drug Investig. 2012 May 1;32(5):319-32. doi: 10.2165/11630930-000000000-00000. [Article]
  6. Tytgat GN: Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol. 2001 May;13 Suppl 1:S29-33. [Article]
  7. Haastrup PF, Thompson W, Sondergaard J, Jarbol DE: Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):114-121. doi: 10.1111/bcpt.13023. Epub 2018 May 24. [Article]
  8. Reimer C, Sondergaard B, Hilsted L, Bytzer P: Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009 Jul;137(1):80-7, 87.e1. doi: 10.1053/j.gastro.2009.03.058. Epub 2009 Apr 10. [Article]
  9. Shin JM, Kim N: Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013 Jan;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25. Epub 2013 Jan 8. [Article]
  10. DailyMed Label: DEXILANT (dexlansoprazole) delayed-release capsules, for oral use [Link]
  11. FDA Approved Drug Products: DEXILANT (dexlansoprazole) Oral Delayed-release capsules or DEXILANT SOLUTAB (dexlansoprazole) delayed-release orally disintegrating tablets (October 2016) [Link]
  12. TWi Pharmaceuticals: Dexlansoprazole MSDS [Link]
PubChem Compound
9578005
PubChem Substance
347827723
ChemSpider
7852369
BindingDB
50247930
RxNav
816346
ChEBI
135931
ChEMBL
CHEMBL1201863
ZINC
ZINC000003830986
PharmGKB
PA166110257
Wikipedia
Dexlansoprazole

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentBarrett's Esophagus / Inflammation1
4CompletedTreatmentGastro-esophageal Reflux Disease (GERD)2
4CompletedTreatmentGastro-esophageal Reflux Disease (GERD) / Proton Pump Inhibitors1
4CompletedTreatmentH Pylori Infection Eradication1
4CompletedTreatmentHelicobacter Pylori Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet30 mg
Tablet60 mg
CapsuleOral
CapsuleOral60.00 mg
Capsule, delayed releaseNasogastric; Oral30 mg
Capsule, delayed releaseNasogastric; Oral60 mg
Capsule, delayed releaseOral60 mg/1
CapsuleOral30 mg
CapsuleOral60 mg
Capsule, delayed release60 mg
Capsule, extended releaseOral30 MG
Capsule, extended releaseOral60 MG
Capsule, delayed releaseOral30 mg
Capsule, delayed releaseOral60 mg
Capsule, delayed releaseOral
Tablet, orally disintegrating, delayed releaseOral30 mg/1
Capsule, delayed release30 mg
CapsuleOral7.500 mg
Capsule, delayed release pelletsOral30 mg/1
Capsule, delayed release pelletsOral60 mg/1
Capsule, coatedOral30 mg
Capsule, coatedOral3000000 mg
Capsule, coatedOral6000000 mg
Capsule, delayed releaseOral6000000 mg
Capsule, delayed releaseOral30 mg/1
Capsule, coatedOral60 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
CA1327010No1994-02-152011-02-15Canada flag
CA2375201No2010-02-092020-06-15Canada flag
US7399485Yes2008-07-152018-11-26US flag
US6328994Yes2001-12-112019-11-17US flag
US7875292Yes2011-01-252019-11-17US flag
US7431942Yes2008-10-072019-11-17US flag
US6462058Yes2002-10-082020-12-15US flag
US6939971Yes2005-09-062020-12-15US flag
US8173158Yes2012-05-082030-09-17US flag
US6664276Yes2003-12-162023-07-30US flag
US8784885Yes2014-07-222024-04-15US flag
US9233103No2016-01-122032-03-05US flag
US9011926No2015-04-212026-02-24US flag
US9238029No2016-01-192026-01-17US flag
US8722084Yes2014-05-132024-04-15US flag
US9145389No2015-09-292020-06-15US flag
US8871273Yes2014-10-282028-07-11US flag
US8461187Yes2013-06-112026-07-17US flag
US8105626Yes2012-01-312027-03-27US flag
US7285668Yes2007-10-232020-12-15US flag
US7790755Yes2010-09-072027-02-02US flag
US9241910No2016-01-262029-03-10US flag
US6238994Yes2001-05-292019-11-17US flag

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.25 mg/mLALOGPS
logP2.84ALOGPS
logP3.03Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)9.35Chemaxon
pKa (Strongest Basic)4.16Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area67.87 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity87.61 m3·mol-1Chemaxon
Polarizability34.5 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fk9-0059000000-f06d77d09a86f5e2bf71
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0v59-0769000000-b68e645e752cc42ba812
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0900000000-2b57a28f448d017c174c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014l-1933000000-25b5d7be37adf65fa45f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0uyr-0930000000-bb49b5d18d287fcc5ad3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0910000000-674886b87ab10a6d4082
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-175.42035
predicted
DeepCCS 1.0 (2019)
[M+H]+177.77835
predicted
DeepCCS 1.0 (2019)
[M+Na]+184.21729
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium-exchanging atpase activity
Specific Function
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name
ATP4A
Uniprot ID
P20648
Uniprot Name
Potassium-transporting ATPase alpha chain 1
Molecular Weight
114117.74 Da
References
  1. Shin JM, Kim N: Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013 Jan;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25. Epub 2013 Jan 8. [Article]
  2. FDA Approved Drug Products: DEXILANT (dexlansoprazole) Oral Delayed-release capsules or DEXILANT SOLUTAB (dexlansoprazole) delayed-release orally disintegrating tablets (October 2016) [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Hydrogen:potassium-exchanging atpase activity
Specific Function
Required for stabilization and maturation of the catalytic proton pump alpha subunit and may also involved in cell adhesion and establishing epithelial cell polarity.
Gene Name
ATP4B
Uniprot ID
P51164
Uniprot Name
Potassium-transporting ATPase subunit beta
Molecular Weight
33366.95 Da
References
  1. Shin JM, Kim N: Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013 Jan;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25. Epub 2013 Jan 8. [Article]
  2. FDA Approved Drug Products: DEXILANT (dexlansoprazole) Oral Delayed-release capsules or DEXILANT SOLUTAB (dexlansoprazole) delayed-release orally disintegrating tablets (October 2016) [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation.
Gene Name
DDAH1
Uniprot ID
O94760
Uniprot Name
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1
Molecular Weight
31121.5 Da
References
  1. Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, Leiper J, Cooke JP: Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013 Aug 20;128(8):845-53. doi: 10.1161/CIRCULATIONAHA.113.003602. Epub 2013 Jul 3. [Article]
  2. Tommasi S, Elliot DJ, Hulin JA, Lewis BC, McEvoy M, Mangoni AA: Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance. Sci Rep. 2017 Jun 6;7(1):2871. doi: 10.1038/s41598-017-03069-1. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Curator comments
AAlthough in vitro studies indicated that dexlansoprazole has the potential to inhibit CYP2C19 in vivo, an in vivo drug- drug interaction study in mainly CYP2C19 extensive and intermediate metabolizers has shown that dexlansoprazole does not affect the pharmacokinetics of CYP2C19 substrates.
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Goh KL, Choi MG, Hsu PI, Chun HJ, Mahachai V, Kachintorn U, Leelakusolvong S, Kim N, Rani AA, Wong BC, Wu J, Chiu CT, Shetty V, Bocobo JC, Chan MM, Lin JT: Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region. J Neurogastroenterol Motil. 2016 Jul 30;22(3):355-66. doi: 10.5056/jnm15150. [Article]
  2. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [Article]
  3. FDA Approved Drug Products: DEXILANT (dexlansoprazole) Oral Delayed-release capsules or DEXILANT SOLUTAB (dexlansoprazole) delayed-release orally disintegrating tablets (October 2016) [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. FDA Approved Drug Products: DEXILANT (dexlansoprazole) Oral Delayed-release capsules or DEXILANT SOLUTAB (dexlansoprazole) delayed-release orally disintegrating tablets (October 2016) [Link]

Drug created at November 18, 2007 18:24 / Updated at March 03, 2024 02:17